US 2009/0263385 A1 · Breast carcinoma treatment method

Abstract

The instant invention is an in-vivo treatment method directed against living epithelial cells in the human breast, and uses a modified ductal lavage technique to infuse a purposely formulated treatment fluid into pre-chosen individual ducts in the human breast for reaction with such epithelial cells as then are present within the ducts. The prepared treatment fluid, at a minimum, comprises: at least one preselected Complement-fixing antibody (or preferably an admixture of different Complement-fixing antibodies) directed at specific antigens, haptens or epitopes which are characteristically present on normal, atypical, or malignant breast epithelial cells in-vivo; the recognized chemical components for activating and fixing Complement in-situ; and a biocompatible fluid carrier. The treatment method can be employed as a therapeutic process in-vivo against a presently existing breast disorder, neoplasm, or carcinoma; but also may be used in-vivo as a preventative procedure performed prophylactically in advance of the patient receiving a clinical diagnosis of breast malignancy (e.g., ductal, medullary, or lobular carcinoma). It can also be used to treat a breast with atypia, premalignancy, carcinoma in-situ, or carcinoma (when not treated with total mastectomy), and can be used as a prophylactic treatment in the contralaterial breast.

Claims16

Dependent claims

A method for therapeutically treating a living human patient believed to be afflicted with an identifiable type of atypical or abnormal epithelial cell in the breast, said method comprising the steps of:

identifying at least one duct in the nipple of the human breast as a target for therapeutic treatment;
introducing a predetermined quantity of a formulated fluid into the lumen of said identified duct as a therapeutic treatment, wherein said introduced treatment fluid comprises
(i) at least one Complement-fixing antibody directed against and able to bind to specific antigens, haptens, or epitopes which are characteristically present on normal, atypical, or malignant breast epithelial cells in-vivo,
(ii) Complement proteins forming the chemical components of Complement and sufficient for initiating the cascade of reactions for in-vivo activation and fixation of Complement by said antibody after becoming bound to a breast epithelial cell, and
(iii) a biocompatible fluid carrier;
allowing said introduced treatment fluid to react in-situ for a preselected time period with such breast epithelial cells as are then present within the lumen of said identified duct, whereby at least a portion of said antibodies in said introduced treatment fluid become bound to the breast epithelial cells, and there is an in-situ activation and fixing of Complement proteins by said antibodies after becoming bound to the breast epithelial cells;
and
removing said reacted treatment fluid from the lumen of said identified duct in the human breast.

5 more elements

A method for prophylactically treating a living human patient suspected of becoming afflicted with an identifiable type of atypical or abnormal epithelial cell in the breast, said method comprising the steps of:

identifying at least one duct in the nipple of the human breast as a target for prophylactic treatment;
introducing a predetermined quantity of a formulated fluid into the lumen of said identified duct as a prophylactic treatment, wherein said introduced treatment fluid comprises
(i) at least one Complement-fixing antibody directed against and able to bind to specific antigens, haptens, or epitopes which are characteristically present on normal, atypical, or malignant breast epithelial cells in-vivo,
(ii) Complement proteins forming the chemical components of Complement and sufficient for initiating the cascade of reactions for in-vivo activation and fixation of Complement by said antibody after becoming bound to a breast epithelial cell, and
(iii) a biocompatible fluid carrier;
allowing said introduced treatment fluid to react in-situ for a preselected time period with such breast epithelial cells as are then present within the lumen of said identified duct, whereby at least a portion of said antibodies in said introduced treatment fluid become bound to the breast epithelial cells, and there is an in-situ activation and fixing of Complement proteins by said antibodies after becoming bound to the breast epithelial cells;
and
removing said reacted treatment fluid from the lumen of said identified duct in the human breast.

5 more elements

Dependencies are inferred from the claim text.

Breast carcinoma treatment method

Life of this patent

Breast carcinoma treatment method

Life of this patent

Abstract

Claims16